6998 — Edding Genor group Share News
0.000.00%
Last trade - 00:00- HK$3.32bn
- HK$3.87bn
- CNY2.49bn
Brief: Edding Genor Posts Net Profit Increased To Rmb399.3 Million In 2025
Brief: Genor Biopharma Says NMPA Granted New Drug Application Approval For Lerociclib (Gb491)
Brief: Genor Biopharma, Its Unit & Edding Group Entered Into Merger Agreement
Brief: Genor Biopharma Says Guo Feng Tendered His Resignation As Chairman
Brief: Genor Biopharma Holdings Posts H1 Net Income Attributable RMB -125.7 Million
Brief: Genor Biopharma Says On 2 Aug, Co Entered License Deal And Stock Purchase Deal With TRC 2004
Brief: Jhbp Cy Says NMPA Accepts New Drug Application For Gb491 (Lerociclib)
Brief: Genor Biopharma Posts HY Loss Attributable RMB274.6 Million
Brief: JHBP CY Notified By NMPA That New Product Application Approval Of Geptanolimab Was Not Granted
Brief: Genor Biopharma Posts FY Loss Of RMB730.4 Million
Brief: Jhbp Cy Says China's Nmpa Accepted New Drug Application For Gb491 (Lerociclib) With Fluvestran
Over a dozen Chinese-based firms say they have minimal exposure to SVB (updated)
Brief: Genor Biopharma Says Maintains Accounts At Silicon Valley Bank With Minimal Cash Balance
Brief: Jhbp Cy To Launch Of Phase I/II Clinical Trial Of Gb261 In China
Brief: Genor Biopharma Posts HY Adjusted Loss RMB380.7 Million
China's Genor Biopharma soars most on record on deal to jointly develop mRNA products
Brief: Jhbp Cy - Entered Into Cooperative Development Agreement With Suzhou Abogen Biosciences
Brief: JHBP CY Says Obtained Investigational New Drug Approval From National Medical Products Administration
Brief: Jhbp Cy Says NMPA Grants New Approval For Phase I/Ii Clinical Trials Of Gb261 (Cd20/Cd3 Bsab)